Latest news with #ChristianHowell
Yahoo
2 days ago
- Health
- Yahoo
Cognito's Spectris AD slows Alzheimer's disease progression in trial
Cognito Therapeutics has reported outcomes from a post hoc analysis of its OVERTURE feasibility trial, indicating that the investigational Spectris AD therapy can slow the progression of Alzheimer's disease. The device utilises non-invasive neuromodulation with synchronised light and sound at a gamma frequency to restore disrupted brain activity in Alzheimer's patients. The study involved 76 mild-to-moderate affected subjects. It included a randomised six-month controlled phase and a subsequent 12-month open-label extension. During the controlled phase, one-hour treatments with the device daily led to 4.83 months of preserved daily activity, 4.56 and 4.09 months of delayed cognitive decline and whole-brain atrophy, respectively. Subjects who received the device's treatment showed a delay in progression of the disease compared to those in the sham treatment group. Specifically, subjects initially assigned to Spectris AD and later treated with SPECTRIS in the open-label extension study showed a slower progression to the same degree of decline that the sham group experienced during six months. Tailored for at-home use, Spectris AD has been granted breakthrough device designation by the US Food and Drug Administration (FDA) and is now under assessment in the HOPE pivotal trial. Cognito Therapeutics CEO Christian Howell said: 'Our brains are electrical systems, and Alzheimer's disrupts the rhythms that govern memory, cognition, and our ability to function. 'Spectris AD represents a new class of therapy, one based in physics, that restores these natural neural oscillations without relying on a chemistry-based pharmacologic therapy. These findings show the potential to meaningfully slow disease progression by leveraging the potential of neuromodulation.' Last year, Cognito enrolled the first subject in a biomarker substudy within the HOPE trial evaluating the sensory stimulation device in Alzheimer's patients. "Cognito's Spectris AD slows Alzheimer's disease progression in trial" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
25-03-2025
- Health
- Yahoo
Cognito Therapeutics to Present New Data on Spectris'™ Impact on Brain Structure in Alzheimer's Disease at AD/PD 2025
- New findings, based on MRI imaging analyses, demonstrate Spectris' potential to preserve brain structure and slow neurodegeneration in Alzheimer's disease CAMBRIDGE, Mass., March 25, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced it will present new clinical data from its OVERTURE study at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases, taking place April 1-5, 2025, in Vienna, Austria. The presentations highlight new data from participants on Spectris™, an investigational gamma sensory stimulation therapy, demonstrating its potential to modulate brain function, preserve structural integrity, and slow neurodegeneration in Alzheimer's disease (AD). "We are excited to share this compelling new data at AD/PD 2025, reinforcing Spectris™ as a potential disease-modifying intervention," said Christian Howell, CEO of Cognito Therapeutics. "The findings build on our previous research, showing that preserving brain connectivity and structure through non-invasive neuromodulation could significantly impact disease progression in Alzheimer's patients." Poster Presentation Details: Sensory Evoked Gamma Oscillation Correlates with Brain Morphology in Alzheimer's DiseaseDate/Time: Wednesday, April 2, 8:00 - 10:00 am CETPresenter: Mihaly Hajos PhD, Scientific Advisor, Cognito Therapeutics Spectris™ Treatment Preserves Corpus Callosum Integrity in Alzheimer's Disease: A Comparative StudyDate/Time: Wednesday, April 2, 8:00 - 10:00 am CETPresenter: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics "These new data further support Spectris™ as a potential disease-modifying therapy for Alzheimer's," said Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics. "Our posters at AD/PD 2025 show that Spectris™ preserves corpus callosum integrity, which is critical for cognitive function, and that gamma stimulation correlates with brain structure. Together, these findings reinforce our approach to non-invasive neuromodulation and its potential to slow neurodegeneration. We look forward to validating these results in our ongoing HOPE trial." For more information about the AD/PD 2025 conference, visit: About Cognito Therapeutics Cognito Therapeutics is a late-stage clinical neurotechnology company pioneering disease-modifying treatments for neurodegenerative diseases. Its lead product, Spectris™, uses non-invasive auditory and visual neuromodulation to enhance gamma frequency brain activity, with the goal of slowing brain atrophy and functional decline in Alzheimer's disease. Cognito is committed to developing transformative, technology-driven interventions to address unmet needs in the treatment of CNS diseases. Cognito is headquartered in Cambridge, MA. For more information, visit and follow @cognitotx. View source version on Contacts Media Contact: Kimberly HaKKH
